Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Free Cash Flow (2022 - 2025)

Stoke Therapeutics has reported Free Cash Flow over the past 4 years, most recently at -$31.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$31.0 million for Q4 2025, down 33.51% from a year ago — trailing twelve months through Dec 2025 was $44.9 million (up 151.68% YoY), and the annual figure for FY2025 was $44.9 million, up 151.68%.
  • Free Cash Flow for Q4 2025 was -$31.0 million at Stoke Therapeutics, down from -$30.4 million in the prior quarter.
  • Over the last five years, Free Cash Flow for STOK hit a ceiling of $131.8 million in Q1 2025 and a floor of -$31.0 million in Q4 2025.
  • Median Free Cash Flow over the past 4 years was -$22.1 million (2023), compared with a mean of -$10.0 million.
  • Biggest five-year swings in Free Cash Flow: crashed 166.86% in 2023 and later skyrocketed 636.25% in 2025.
  • Stoke Therapeutics' Free Cash Flow stood at -$22.8 million in 2022, then increased by 8.36% to -$20.9 million in 2023, then decreased by 11.33% to -$23.2 million in 2024, then plummeted by 33.51% to -$31.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$31.0 million (Q4 2025), -$30.4 million (Q3 2025), and -$25.4 million (Q2 2025) per Business Quant data.